Surrozen (SRZN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Executive summary
The annual meeting will be held virtually on May 13, 2026, with voting available online, by phone, or by mail.
Stockholders will vote on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.
Holders of record as of March 18, 2026, are entitled to vote; a quorum requires one-third of outstanding shares.
Voting matters and shareholder proposals
Election of two Class II directors (Mace Rothenberg, M.D. and David J. Woodhouse, Ph.D.) for terms expiring in 2029.
Ratification of Ernst & Young LLP as independent auditor for 2026.
Advisory vote on executive compensation and on the preferred frequency of such votes (Board recommends annual frequency).
Stockholders may submit proposals for the 2027 meeting by specified deadlines and procedures.
Board of directors and corporate governance
Board consists of eight directors divided into three classes with staggered terms.
Majority of directors are independent per Nasdaq standards; CEO and Chair roles are separated.
Three standing committees: audit, compensation, and nominating/corporate governance, each with defined responsibilities and independent members.
Board and committees met regularly in 2025; all directors except one attended at least 75% of meetings.
Board emphasizes diversity, integrity, and relevant experience in director nominations.
Latest events from Surrozen
- Virtual annual meeting to vote on directors, auditor, and executive pay matters.SRZN
Proxy filing1 Apr 2026 - Multi-functional antibodies targeting Wnt, VEGF, and IL-6 address major unmet needs in retinal disease.SRZN
Corporate presentation24 Mar 2026 - Biotech firm launches $200M shelf, including $50M ATM with TD Cowen, targeting ophthalmology.SRZN
Registration filing23 Mar 2026 - Cash rose to $89M, net loss widened to $242M, IND for SZN-8141 expected H2 2026.SRZN
Q4 202523 Mar 2026 - Advancing multispecific antibody therapies for retinal diseases, aiming for superior outcomes.SRZN
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Lead Wnt/VEGF bispecifics advance toward IND in 2026, backed by strong IP and financials.SRZN
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Bispecific antibodies targeting Wnt signaling may transform retinal disease treatment by 2026.SRZN
H.C. Wainwright 27th Annual Global Investment Conference3 Feb 2026 - Tissue-targeted Wnt therapies show promise in liver and eye diseases, with pivotal data ahead.SRZN
Guggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026 - Lead SAH therapy shows early safety, with key data and financial milestones expected in 2025.SRZN
Stifel 2024 Healthcare Conference13 Jan 2026